ALLAY-LID-I

Efficacy and Safety of Amantadine Hydrochloride (HCl) ER Tablets to Treat Parkinson's Disease Patients With LID

Thématique(s) / pathologie(s)

  • Maladie de Parkinson

Objectifs

Plus d'informations disponibles sur : https://clinicaltrials.gov/ct2/show/record/NCT02153645?term=osmotica&cond=Parkinson&rank=2

Promoteur

Adamas Pharmaceuticals, Inc.

Publication(s) scientifique(s)

  • Rascol O, Tönges L, deVries T, Jaros M, Quartel A, Jacobs D; ALLAY-LID I and ALLAY-LID II study groups. Immediate-release/extended-release amantadine (OS320) to treat Parkinson's disease with levodopa-induced dyskinesia: Analysis of the randomized, controlled ALLAY-LID studies. Parkinsonism Relat Disord. 2022 Mar;96:65-73. 

    Publication ALLAY-LID-I

Statut

Résultats publiés

Centres participants

Partager

Mis à jour le 20 avril 2023